Note to editors from the Accelerating Access Initiative (AAI)

During the 12 months to March 2005, the estimated number of people living with HIV in developing countries treated with ARVs provided by the Accelerating Access Initiative (AAI) companies has increased to more than 427,000. This is a 47 per cent increase over 2004 figures, with over 130,000 people being initiated on treatment during 2004. The number of patients in Africa reached a total of 216,000 patients, an increase in excess of 121 per cent on the previous year. These results demonstrate the ongoing commitment of the seven research-based pharmaceutical companies involved in the AAI – Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Roche, and Merck & Co., Inc. For further information:

In the US: Samir A. Khalil, Merck & Co., Inc
Tel. +1.908.423.6440

In Switzerland: Maria Vigneau, Roche
Tel: +41.61.688.9291.